Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology

Open Access 15-04-2024 | Transcatheter Aortic Valve Implantation | Original Paper

Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo—the POLESTAR trial

Authors: Joris F. Ooms, Kristoff Cornelis, Harindra C. Wijeysundera, Bert Vandeloo, Jan Van Der Heyden, Jan Kovac, David Wood, Albert Chan, Joanna Wykyrzykowska, Liesbeth Rosseel, Michael Cunnington, Frank van der Kley, Benno Rensing, Michiel Voskuil, David Hildick-Smith, Nicolas M. Van Mieghem

Published in: Clinical Research in Cardiology

Login to get access

Abstract

Background

Transcatheter aortic valve implantation (TAVI) serves a growing range of patients with severe aortic stenosis (AS). TAVI has evolved to a streamlined procedure minimizing length of hospital stay.

Aims

To evaluate the safety and efficacy of an early discharge (ED) strategy after TAVI.

Methods

We performed an international, multi-center, prospective observational single-arm study in AS patients undergoing TAVI with the ACURATE valve platform. Eligibility for ED was assessed prior to TAVI and based on prespecified selection criteria. Discharge ≤ 48 h was defined as ED. Primary Valve Academic Research Consortium (VARC)-3-defined 30-day safety and efficacy composite endpoints were landmarked at 48 h and compared between ED and non-ED groups.

Results

A total of 252 patients were included. The median age was 82 [25th–75th percentile, 78–85] years and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score was 2.2% [25th–75th percentile, 1.6–3.3]. ED and non-ED were achieved in 173 (69%) and 79 (31%) patients respectively. Monitoring for conduction disturbances was the principal reason for non-ED (33%). Overall, at 30 days, all-cause mortality was 1%, new permanent pacemaker rate was 4%, and valve- or procedure-related rehospitalization was 4%. There was no difference in the primary safety and efficacy endpoint between the ED and non-ED cohorts (OR 0.84 [25th–75th percentile, 0.31–2.26], p = 0.73, and OR 0.97 [25th–75th percentile, 0.46–2.06], p = 0.94). The need for rehospitalization was similarly low for ED and non-ED groups.

Conclusion

Early discharge after TAVI with the ACURATE valve is safe and feasible in selected patients. Rhythm monitoring and extended clinical observation protracted hospital stay.

Graphical Abstract

Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo, an international multi-center, prospective observational single-arm study. OR, odds ratio (95% confidence interval); VARC, Valve Academic Research Consortium
Literature
1.
Cribier A (2012) Development of transcatheter aortic valve implantation (TAVI): a 20-year odyssey. Arch Cardiovasc Dis 105:146–152CrossRefPubMed
2.
Barbanti M, Buccheri S, Rodes-Cabau J et al (2017) Transcatheter aortic valve replacement with new-generation devices: a systematic review and meta-analysis. Int J Cardiol 245:83–89CrossRefPubMed
3.
Costa G, Barbanti M, Rosato S et al (2022) Real-world multiple comparison of transcatheter aortic valves: insights from the multicenter OBSERVANT II study. Circ Cardiovasc Interv 15:e012294CrossRefPubMed
4.
Villablanca PA, Mohananey D, Nikolic K et al (2018) Comparison of local versus general anesthesia in patients undergoing transcatheter aortic valve replacement: a meta-analysis. Catheter Cardiovasc Interv 91:330–342CrossRefPubMed
5.
Winter MP, Bartko P, Hofer F et al (2020) Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. Sci Rep 10:15568CrossRefPubMedPubMedCentral
6.
Babaliaros V, Devireddy C, Lerakis S et al (2014) Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv 7:898–904CrossRefPubMed
7.
Didier R, Le Breton H, Eltchaninoff H et al (2022) Evolution of TAVI patients and techniques over the past decade: the French TAVI registries. Arch Cardiovasc Dis 115:206–213CrossRefPubMed
8.
Arora S, Strassle PD, Kolte D et al (2018) Length of stay and discharge disposition after transcatheter versus surgical aortic valve replacement in the United States. Circ Cardiovasc Interv 11:e006929CrossRefPubMed
9.
Wayangankar SA, Elgendy IY, Xiang Q et al (2019) Length of stay after transfemoral transcatheter aortic valve replacement: an analysis of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC Cardiovasc Interv 12:422–430CrossRefPubMed
10.
Barbanti M, van Mourik MS, Spence MS et al (2019) Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention 15:147–154CrossRefPubMed
11.
Wood DA, Lauck SB, Cairns JA et al (2019) The Vancouver 3M (multidisciplinary, multimodality, but minimalist) clinical pathway facilitates safe next-day discharge home at low-, medium-, and high-volume transfemoral transcatheter aortic valve replacement centers: the 3M TAVR Study. JACC Cardiovasc Interv 12:459–469CrossRefPubMed
12.
Hokken TW, Muhemin M, Okuno T et al (2022) Impact of membranous septum length on pacemaker need with different transcatheter aortic valve replacement systems: the INTERSECT registry. J Cardiovasc Comput Tomogr 16:524–530CrossRefPubMed
13.
Ooms JF, Cornelis K, Stella PR et al (2022) Rationale and design of the project to look for early discharge in patients undergoing TAVR with ACURATE (POLESTAR Trial). Cardiovasc Revasc Med 44:71–77CrossRefPubMed
14.
Varc Writing C, Genereux P, Piazza N et al (2021) Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 77:2717–2746CrossRef
15.
Barker M, Sathananthan J, Perdoncin E et al (2022) Same-day discharge post-transcatheter aortic valve replacement during the COVID-19 pandemic: the multicenter PROTECT TAVR study. JACC Cardiovasc Interv 15:590–598CrossRefPubMedPubMedCentral
16.
Kamioka N, Wells J, Keegan P et al (2018) Predictors and clinical outcomes of next-day discharge after minimalist transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv 11:107–115CrossRefPubMed
17.
Krishnaswamy A, Isogai T, Agrawal A et al (2022) Feasibility and safety of same-day discharge following transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv 15:575–589CrossRefPubMed
18.
Scotti A, Pagnesi M, Kim WK et al (2022) Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2. EuroIntervention 18:804–811CrossRefPubMedPubMedCentral
19.
Elzanaty AM, Maraey A, Elbadawi A et al (2022) Early versus late discharge after transcatheter aortic valve replacement and readmissions for permanent pacemaker implantation. Catheter Cardiovasc Interv 100:245–253CrossRefPubMed
20.
Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620CrossRefPubMed
21.
Manoharan G, Grube E, Van Mieghem NM et al (2020) Thirty-day clinical outcomes of the Evolut PRO self-expanding transcatheter aortic valve: the international FORWARD PRO study. EuroIntervention 16:850–857CrossRefPubMed
22.
Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331CrossRefPubMed
23.
Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695–1705CrossRefPubMed
24.
Popma JJ, Deeb GM, Yakubov SJ et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706–1715CrossRefPubMed
Metadata
Title
Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo—the POLESTAR trial
Authors
Joris F. Ooms
Kristoff Cornelis
Harindra C. Wijeysundera
Bert Vandeloo
Jan Van Der Heyden
Jan Kovac
David Wood
Albert Chan
Joanna Wykyrzykowska
Liesbeth Rosseel
Michael Cunnington
Frank van der Kley
Benno Rensing
Michiel Voskuil
David Hildick-Smith
Nicolas M. Van Mieghem
Publication date
15-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-024-02436-z

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits